321 HARRISON AVENUE, BOSTON, MA
Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
Announces Second Quarter 2025 Financial Results and Business Updates
Shareholder votes
Financial Results, Reg. FD
Annual Report to Security Holders
Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
Investor Presentation
Changes in Board, Management or Compensation
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership